(Q26748936)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6273289&resulttype=core&format=json

13 May 2020

1 reference

cholinesterase inhibitors

1 reference

30 January 2021

Maria Laura Bolognesi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Federica Prati

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Andrea Cavalli

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

2016

0 references

8 April 2016

1 reference

30 January 2021

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

30 January 2021

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

466

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

3 June 2020

copyright license

1 reference

30 January 2021

0 references

The efficiency of multi-target drugs: the network approach might help drug design

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Network pharmacology: the next paradigm in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Network medicine: a network-based approach to human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

New approaches to treating Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Multi-target-directed ligands to combat neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

A small molecule targeting the multifactorial nature of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Polypharmacology in a single drug: multitarget drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Can we rationally design promiscuous drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Designing multiple ligands - medicinal chemistry strategies and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

From magic bullets to designed multiple ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Molecular complexity and its impact on the probability of finding leads for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

The role of fragment-based and computational methods in polypharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Fragments, network biology and designing multiple ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Combination therapy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

NR2B-containing NMDA receptors expression and their relationship to apoptosis in hippocampus of Alzheimer's disease-like rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Copper, iron and zinc in Alzheimer's disease senile plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

The redox chemistry of the Alzheimer's disease amyloid beta peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Alzheimer's disease, metal ions and metal homeostatic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

From single target to multitarget/network therapeutics in Alzheimer's therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

The case for rejecting the amyloid cascade hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Alzheimer's disease drug-development pipeline: few candidates, frequent failures

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

Investigations of the molecular mechanism of metal-induced Abeta (1-40) amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES21040466

The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27070562

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The physicochemical challenges of designing multiple ligands

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27070562

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3390/MOLECULES21040466

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

PubMed publication ID

27070562

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27070562%20AND%20SRC:MED&resulttype=core&format=json